Anito-cel Offers Competitive Edge Over Carvykti in Multiple Myeloma Trials

Gilead Sciences, in collaboration with Arcellx, has unveiled compelling data for their novel CAR-T therapy, anitocabtagene autoleucel (anito-cel), aimed at treating relapsed or refractory multiple myeloma. The data from the Phase II iMMagine-1 trial highlights an impressive 95% overall response rate among 58 patients, with a significant 62% achieving complete or stringent complete responses. Notably, the therapy demonstrated robust safety features, with the absence of delayed neurotoxicity events and a six-month progression-free survival rate of 90%[1][2]. Analysts argue that these findings position anito-cel as a strong contender against the established CAR-T therapy, Carvykti, by offering a potentially superior risk/benefit profile suitable for outpatient settings[1][3].